SCHEMBL22497240

SCHEMBL22497240

NS(=O)(=O)c1ccn(CC2CCCO2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.42
▸ TSHR P16473 3/20 0.42
▸ CYP2C9 P11712 3/20 0.42
▸ CYP2C19 P33261 3/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ ALDH1A1 P00352 8/20 0.41
▸ POLB P06746 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HPGD P15428 2/20 0.39
▸ RECQL P46063 1/20 0.37
▸ NR2F2 P24468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29284933 0.93 TSHR (0.33) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL29284936 0.93 TSHR (0.33) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL22524842 0.80 KDM4E (0.37) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL29284959 0.79 CA2 (0.39) MEN1KMT2ARAB9A
SCHEMBL30366107 0.78 CA1 (0.44) ALDH1A1
SCHEMBL22497280 0.76 KDM4E (0.36) KDM4ECYP2C9CYP2C19CYP1A2ALDH1A1
SCHEMBL24915274 0.74 KDM4E (0.42) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL25862304 0.73 KMT2A (0.39) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL25617367 0.72 KDM4E (0.40) KDM4ETSHRCYP2C9CYP2C19CYP1A2
SCHEMBL25859573 0.72 KDM4E (0.40) KDM4ETSHRCYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012392-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-06-18 — — US disclosed
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-10-08 — — US disclosed
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-10-08 — — US disclosed
CN-111315733-A Novel sulfonamide carboxamide compounds 英夫拉索姆有限公司 2020-06-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, PYCARD KDM4E 1872/4885TSHR 4116/4885CYP2C9 731/4885
US-12012392-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 KDM4E 1851/4885TSHR 3912/4885CYP2C9 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback